Calcium handling and atrial fibrillation

Jordi Heijman1, Niels Voigt, Stanley Nattel

  • 1Division of Experimental Cardiology, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.

Insights

Atrial fibrillation (AF) involves abnormal calcium handling in the heart, leading to arrhythmias. Targeting these calcium issues offers new therapeutic strategies for treating AF.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Electrophysiology

Background:

  • Atrial fibrillation (AF) is a common cardiac arrhythmia with significant health risks.
  • Abnormal calcium (Ca2+) handling is increasingly recognized as a key factor in AF.
  • This includes contributions to ectopic beats, reentry circuits, and reduced atrial contractility.

Purpose of the Study:

  • To review the role of altered atrial calcium handling in AF.
  • To discuss the causes and consequences of these calcium abnormalities.
  • To explore potential therapeutic strategies targeting calcium handling for AF treatment.

Main Methods:

  • Literature review of recent research on calcium handling and AF.
  • Analysis of the pathophysiological mechanisms linking calcium dysregulation to AF.
  • Synthesis of findings to identify therapeutic implications.

Main Results:

  • Abnormal Ca2+ handling is central to AF induction and maintenance.
  • Specific Ca2+ handling defects contribute to AF-specific electrical and mechanical dysfunction.
  • These abnormalities present potential targets for novel AF therapies.

Conclusions:

  • Altered atrial Ca2+ handling is a critical determinant of AF pathophysiology.
  • Understanding these mechanisms provides a basis for developing targeted AF treatments.
  • Modulating Ca2+ handling represents a promising therapeutic avenue for managing atrial fibrillation.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...